Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.
Risk & Volatility
Creative Medical Technology has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Profitability
This table compares Creative Medical Technology and Cognition Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -63.05% | -60.42% |
| Cognition Therapeutics | N/A | -150.93% | -100.82% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $11,000.00 | 829.51 | -$5.29 million | ($3.80) | -1.37 |
| Cognition Therapeutics | N/A | N/A | -$25.79 million | ($0.97) | -0.44 |
Creative Medical Technology has higher revenue and earnings than Cognition Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Creative Medical Technology and Cognition Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 0 | 0 | 0 | 0 | 0.00 |
| Cognition Therapeutics | 0 | 1 | 5 | 1 | 3.00 |
Cognition Therapeutics has a consensus price target of $8.30, suggesting a potential upside of 1,828.44%. Given Cognition Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Creative Medical Technology.
Institutional & Insider Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are owned by institutional investors. 2.8% of Creative Medical Technology shares are owned by company insiders. Comparatively, 20.8% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Cognition Therapeutics beats Creative Medical Technology on 8 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
